Essential Premium

AI Drug Discovery Reaches the IPO Market

Iambic Therapeutics, backed by Coatue, Nvidia, Millennium, and Two Sigma, is bringing its AI-based drug development to public investors.

Legal Forum Winter Roundtable 2027

March 3-4, 2027 | Apella

Are Institutions Funding AI Abundance or Catastrophe?

Every dollar backing the AI buildout is a wager that AI will deliver extraordinary gains rather than disaster. Asset owners are in on that bet, whether they realize it or not.

Sponsored

From Equitizing Cash to Core Holdings: How Asset Owners are Rethinking ETFs

Is the S&P 500's Concentrated Rally Starting to Diversify?

2026 Hedge Fund Roundtable | The AI Opportunity Through a Hedge Fund Lens

These Hedgies Invested in the Latest Unicorns

Hedge funds including Seligman Ventures and Maverick Capital were among the investors behind some of the companies that became unicorns in August.

Related Content

AI Meets Biotech — and Hedge Funds Are Buying In

Stephen Taub

Ken Tropin Plays the Long Game With Graham Capital

Michelle Celarier

Whale Rock Makes Rare VC Bet on Harvey at $15.5B Valuation

Stephen Taub

Corporate Funds & Insurance Portfolios Roundtable 2027

March 9-10, 2027

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram